While molecularly targeted therapies based on actionable biomarkers are improving outcomes for patients with lung cancer, access to biomarker testing continues to hinder equitable and comprehensive care for underserved patients. In this episode, CANCER BUZZ TV speaks with Tom Lycan, DO, MHS, assistant professor of Hematology & Oncology at the Wake Forest School of Medicine, about a practical tool that can provide a care plan roadmap for providers and patients to mitigate precision medicine disparities.
“[The 4R Care Sequences pathway] gives an overarching view of what they [patients] are looking for in the immediate future and also down the road, and it can be a very helpful thing for patients and navigators, and honestly for clinicians...when I’m meeting with patients in-clinic, it helps me to just point to this and go through and review their pathway with the patient, so that I also can reframe everything in how we’re coming up with a [treatment] plan together.”—Tom Lycan, DO, MHS
Tom Lycan, DO, MHS
Assistant Professor
Hematology & Oncology, Department of Internal Medicine
Wake Forest School of Medicine
Winston-Salem, NC
This episode was developed in connection with the ACCC education program Eliminating Precision Medicine Disparities, in partnership with the LUNGevity Foundation, and is supported by Janssen Oncology and Pfizer.
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
